Daniel A. Rushing

2.5k total citations
42 papers, 1.5k citations indexed

About

Daniel A. Rushing is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Daniel A. Rushing has authored 42 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 8 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Daniel A. Rushing's work include Sarcoma Diagnosis and Treatment (21 papers), Cardiac tumors and thrombi (6 papers) and Lung Cancer Research Studies (5 papers). Daniel A. Rushing is often cited by papers focused on Sarcoma Diagnosis and Treatment (21 papers), Cardiac tumors and thrombi (6 papers) and Lung Cancer Research Studies (5 papers). Daniel A. Rushing collaborates with scholars based in United States, Germany and United Kingdom. Daniel A. Rushing's co-authors include Keith A. Rodvold, Duane A. Tewksbury, Stephen C. Piscitelli, Fatih Akisik, Jonas Rydberg, Arumugam Rajesh, Kumaresan Sandrasegaran, John Henley, Kristen N. Ganjoo and Denise K. Reinke and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Daniel A. Rushing

41 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel A. Rushing United States 20 771 564 286 283 270 42 1.5k
Javier Martínez‐Trufero Spain 20 1.1k 1.5× 976 1.7× 175 0.6× 533 1.9× 199 0.7× 124 2.0k
Bernadette Liegl‐Atzwanger Austria 25 1.3k 1.7× 863 1.5× 372 1.3× 528 1.9× 335 1.2× 109 2.2k
Giuseppe Badalamenti Italy 25 764 1.0× 1.0k 1.8× 207 0.7× 441 1.6× 621 2.3× 144 2.3k
T Türsz France 14 1.5k 1.9× 1.2k 2.2× 155 0.5× 325 1.1× 208 0.8× 38 1.9k
Henk H. Hartgrink Netherlands 26 1.2k 1.5× 632 1.1× 349 1.2× 791 2.8× 466 1.7× 60 2.3k
Marco Gambarotti Italy 28 1.6k 2.0× 677 1.2× 251 0.9× 436 1.5× 514 1.9× 150 2.7k
César Serrano Spain 24 1.3k 1.6× 459 0.8× 1.1k 3.9× 585 2.1× 226 0.8× 103 2.1k
Sophie Cousin France 21 862 1.1× 1.2k 2.1× 58 0.2× 191 0.7× 320 1.2× 126 1.9k
Federica Bertolini Italy 28 946 1.2× 1.2k 2.1× 297 1.0× 931 3.3× 274 1.0× 120 2.2k
Ryo Wada Japan 20 321 0.4× 437 0.8× 89 0.3× 416 1.5× 225 0.8× 140 1.2k

Countries citing papers authored by Daniel A. Rushing

Since Specialization
Citations

This map shows the geographic impact of Daniel A. Rushing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Rushing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Rushing more than expected).

Fields of papers citing papers by Daniel A. Rushing

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Rushing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Rushing. The network helps show where Daniel A. Rushing may publish in the future.

Co-authorship network of co-authors of Daniel A. Rushing

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel A. Rushing. A scholar is included among the top collaborators of Daniel A. Rushing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel A. Rushing. Daniel A. Rushing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Davis, Lara E., Vanessa Bolejack, Christopher W. Ryan, et al.. (2019). Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. Journal of Clinical Oncology. 37(16). 1424–1431. 174 indexed citations
2.
Villalobos, Víctor M., Gary Mo, Mark Agulnik, et al.. (2019). Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma. Cancer Medicine. 9(3). 882–893. 2 indexed citations
3.
Hensley, Martee L., Shreyaskumar Patel, Margaret von Mehren, et al.. (2017). Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecologic Oncology. 146(3). 531–537. 46 indexed citations
4.
Attia, Steven, Vanessa Bolejack, Kristen N. Ganjoo, et al.. (2017). A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results.. Journal of Clinical Oncology. 35(15_suppl). 11005–11005. 29 indexed citations
5.
Villalobos, Víctor M., Mark Agulnik, Seth M. Pollack, et al.. (2016). Abstract CT145: A phase I open-label study to evaluate the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin (Dox) in patients with advanced soft tissue sarcoma (STS). Cancer Research. 76(14_Supplement). CT145–CT145. 2 indexed citations
6.
Schuetze, Scott M., J. Kyle Wathen, David R. Lucas, et al.. (2015). SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma. Cancer. 122(6). 868–874. 79 indexed citations
7.
Widemann, Brigitte C., Denise K. Reinke, Lee J. Helman, et al.. (2013). SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs).. Journal of Clinical Oncology. 31(15_suppl). 10522–10522. 19 indexed citations
8.
Ganjoo, Kristen N., Lee D. Cranmer, James E. Butrynski, et al.. (2011). A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma. Oncology. 80(1-2). 50–56. 65 indexed citations
9.
Trent, Jonathan C., Margaret von Mehren, Brian L. Samuels, et al.. (2011). A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology. 29(15_suppl). 10006–10006. 48 indexed citations
10.
Jordan, Carol A., et al.. (2007). Topiramate in the Treatment of Neuropathic Pain in Patients with Cancer. PubMed. 4(4). 241–246. 10 indexed citations
11.
Patel, Shreyaskumar, Mary Louise Keohan, Muhammad Wasif Saif, et al.. (2006). Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapy. Cancer. 107(12). 2881–2887. 37 indexed citations
12.
Sandrasegaran, Kumaresan, Arumugam Rajesh, Daniel A. Rushing, et al.. (2005). Gastrointestinal stromal tumors: CT and MRI findings. European Radiology. 15(7). 1407–1414. 142 indexed citations
13.
Sandrasegaran, Kumaresan, Arumugam Rajesh, Daniel A. Rushing, et al.. (2005). Gastrointestinal stromal tumors: CT and MRI findings. Clinical Imaging. 30(1). 72–72. 7 indexed citations
14.
Robins, H. Ian, Dörthe M. Katschinski, Walter Longo, et al.. (1999). A pilot study of melphalan, tumor necrosis factor-α and 41.8 °C whole-body hyperthermia. Cancer Chemotherapy and Pharmacology. 43(5). 409–414. 10 indexed citations
15.
Robins, H. Ian, Daniel A. Rushing, K D Tutsch, et al.. (1997). Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients.. Journal of Clinical Oncology. 15(1). 158–164. 74 indexed citations
16.
Rushing, Daniel A., et al.. (1994). The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer. 74(3). 834–841. 62 indexed citations
17.
Rushing, Daniel A., Stephen C. Piscitelli, Keith A. Rodvold, & Duane A. Tewksbury. (1993). The Disposition of Doxorubicin on Repeated Dosing. The Journal of Clinical Pharmacology. 33(8). 698–702. 11 indexed citations
18.
Piscitelli, Stephen C., Keith A. Rodvold, Daniel A. Rushing, & Duane A. Tewksbury. (1993). Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clinical Pharmacology & Therapeutics. 53(5). 555–561. 114 indexed citations
19.
20.
Rodvold, Keith A., Daniel A. Rushing, & Duane A. Tewksbury. (1988). Doxorubicin clearance in the obese.. Journal of Clinical Oncology. 6(8). 1321–1327. 175 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Javier Martínez‐Trufero Breakdown of academic impact, for papers by Bernadette Liegl‐Atzwanger Breakdown of academic impact, for papers by Giuseppe Badalamenti Breakdown of academic impact, for papers by T Türsz Breakdown of academic impact, for papers by Henk H. Hartgrink Breakdown of academic impact, for papers by Marco Gambarotti Breakdown of academic impact, for papers by César Serrano Breakdown of academic impact, for papers by Sophie Cousin Breakdown of academic impact, for papers by Federica Bertolini Breakdown of academic impact, for papers by Ryo Wada
Rankless by CCL
2026